Proteomic analysis of central nervous system inflammation in multiple sclerosis (ARC Linkage held by University of Adelaide) (2010–2012)
This project aims to identify new therapeutic targets and diagnostics for Multiple Sclerosis (MS) the most common neurological disease in young adults. The estimated economic burden of this disease in Australia is around $2 billion per annum. There is also a large social cost to take into account. In spite of a great deal of research, current therapies are limited. We expect that this research will: lead to new therapies and better diagnostics, which will reduce the financial and human cost of this disease; generate IP with subsequent economic benefits and; expand proteomics technologies which will have flow on effects including economic benefits and benefits to a wide range of basic research.